Meander line slots for mutual coupling reduction

    公开(公告)号:US11742570B2

    公开(公告)日:2023-08-29

    申请号:US17315964

    申请日:2021-05-10

    Abstract: Various examples are provided for meander line (ML) slots, which can be used for mutual coupling reduction. In one example, an antenna array includes first and second patch antenna elements disposed on a first side of a substrate, the first and second patch antenna elements separated by a gap. The antenna array can include a meander line (ML) slot formed in a ground plane disposed on a second side of the substrate. A plurality of ML slots can be aligned with the gap between the first and second patch antenna elements. In another example, a method includes forming first and second antenna elements on a first side of a substrate and forming a ML slot in a ground plane disposed on a second side of the substrate aligned with a gap between the first and second antenna elements.

    Small molecule inhibitors of CDK12/CDK13

    公开(公告)号:US11666578B2

    公开(公告)日:2023-06-06

    申请号:US17053652

    申请日:2019-05-07

    CPC classification number: A61K31/5377

    Abstract: The invention provides compounds and methods of inhibiting a cyclin-dependent kinase, comprising contacting the cyclin-dependent kinase and an effective amount or concentration of a compound of formula (I) wherein variables are as defined herein. Compounds of formula (I) can be highly selective inhibitors of cyclin-dependent kinases such as CDK12/13, relative to other kinases such as casein kinases, such as CK1δ/ε. Compounds can be used in treatment of cancers, such as breast cancer, brain cancer and ovarian cancer.

    Nonmuscle myosin II inhibitors for substance use relapse

    公开(公告)号:US11649234B2

    公开(公告)日:2023-05-16

    申请号:US17250203

    申请日:2019-06-13

    CPC classification number: C07D471/04 C07D471/14 C07D495/14 C07D519/00

    Abstract: The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis/marijuana, nicotine, and activities including gambling Compounds are of general formula (I) with substituents as defined herein.

Patent Agency Ranking